<?xml version="1.0" encoding="UTF-8"?>
<fig id="ijerph-17-05648-f008" orientation="portrait" position="float">
 <label>Figure 8</label>
 <caption>
  <p>Schematic representation of SARS-CoV-2 infection and virus-induced human immune system response. Proposed drugs directed both towards specific SARS-CoV-2 molecular targets and biologic processes are highlighted: inhibitors of SARS-CoV-2 fusion/entry targeting ACE2 receptor, spike protein, TMPRSS2 or HR1 and HR2 epitopes and clathrin-mediated endocytosis (I); molecules against SARS-CoV-2 main protease (II); molecules against viral genome replication (III); CRISPR technologies targeting SARS-CoV-2 RNA genome (IV); modulators of SARS-CoV-2 induced inflammatory response (V) and human neutralizing antibodies (VI). ACE2, angiotensin-converting enzyme 2; TMPRSS2, type 2 transmembrane serine proteases; RdRp, RNA-dependent RNA polymerase; HR1, heptad repeat 1; HR2, heptad repeat 2; HR2P, heptad repeat 2-derived peptides; EK1, a modified OC43-HR2P peptide. Adapted from [
   <xref rid="B223-ijerph-17-05648" ref-type="bibr">223</xref>].
  </p>
 </caption>
 <graphic xlink:href="ijerph-17-05648-g008" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
